title: Angiogenesis and antiangiogenic therapy of colon cancer liver metastasis.
abstract: The fact that tumor growth and metastatic spread relies on angiogenesis has been widely proven and accepted. The understanding of cancer biology and metastasis formation has led to the development of new therapeutic approaches that target tumor biology. The survival and establishment of metastatic lesions depend on a shift in the normal balance of proangiogenic and antiangiogenic factors that favor angiogenesis. Colorectal cancer is one of the leading cancer deaths worldwide. Angiogenesis has been associated with colon cancer progression and metastatic spread, thereby significantly affecting patient survival. New experimental approaches that inhibit angiogenic processes have demonstrated promising antineoplastic effects on metastatic colorectal cancer and are partially being investigated in clinical trials. This review focuses on angiogenesis in colorectal cancer metastasis formation as a target for antiangiogenic therapy, describing the experience from experimental studies and current clinical trials.
authors.affiliation: Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
authors.forename: Oliver
authors.initials: O
authors.lastname: Stoeltzing
authors.forename: Wenbiao
authors.initials: W
authors.lastname: Liu
authors.forename: Niels
authors.initials: N
authors.lastname: Reinmuth
authors.forename: Alexander
authors.initials: A
authors.lastname: Parikh
authors.forename: Syed A
authors.initials: SA
authors.lastname: Ahmad
authors.forename: Young D
authors.initials: YD
authors.lastname: Jung
authors.forename: Fan
authors.initials: F
authors.lastname: Fan
authors.forename: Lee M
authors.initials: LM
authors.lastname: Ellis
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D003110:Colonic Neoplasms / Q000098:blood supply / Q000378:metabolism / Q000473:pathology*; D003510:Cyclohexanes; D016228:Endothelial Growth Factors / Q000502:physiology; D006801:Humans; D008113:Liver Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000556:secondary*; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000503:physiopathology; D000077609:O-(Chloroacetylcarbamoyl)fumagillol; D012717:Sesquiterpenes / Q000494:pharmacology; D013141:Spiro Compounds / Q000494:pharmacology; D019699:Thrombospondins / Q000502:physiology; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism / Q000502:physiology; D014945:Wound Healing / Q000187:drug effects
chemical_list: D020533:Angiogenesis Inhibitors; D003510:Cyclohexanes; D016228:Endothelial Growth Factors; C096036:FR 118487; D012717:Sesquiterpenes; D013141:Spiro Compounds; D019699:Thrombospondins; D042461:Vascular Endothelial Growth Factor A; D000077609:O-(Chloroacetylcarbamoyl)fumagillol